Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomised, placebo-controlled, Phase 3 trials
Papp KA,
Menter MA,
Abe M,
Elewski B,
Feldman SR,
Gottlieb AB,
Langley R,
Luger T,
Thaci D,
Buonanno M,
Gupta P,
Proulx J,
Lan S,
Wolk R; OPT Pivotal 1 and OPT Pivotal 2 Investigators.
British Journal of Dermatology. 7 July 2015 DOI: 10.1111/bjd.14018. [Epub ahead of print]
The management of moderate to severe chronic plaque psoriasis has benefited from the introduction of biological therapies, but unmet needs still remain, especially for oral therapies. Tofacitinib is an orally active agent that blocks signalling of key cytokines implicated in the immune response and inflammatory pathways of psoriasis. The Phase III studies presented in this paper analysed efficacy and safety endpoints.Both studies demonstrated that tofacitinib in both 5 mg and 10 mg twice daily doses is efficacious and well tolerated in the treatment of plaque psoriasis in a large, global population over a 16-week period. The results from these studies support the use of tofacitinib as an innovative oral systemic option for the treatment of patients with psoriasis in the future.
